Table 1.
Baseline characteristics of patients involved in the study.
| Variable | All Patients (N = 32) |
|---|---|
| Sex | |
| Female | 12 |
| Male | 20 |
| Age | |
| <60 | 10 |
| ≥60 | 22 |
| Histology | |
| Squamous | 10 |
| Non-Squamous | 21 |
| Immunotherapy treatment | |
| Pembrolizumab | 9 |
| Nivolumab | 15 |
| Atezolizumab | 8 |
| PDL1 status | |
| 0% | 8 |
| 1–4% | 3 |
| 5–49% | 8 |
| ≥50% | 7 |
| Undetermined | 6 |
| Mutation status | |
| No | 30 |
| EGFR | 1 |
| ROS1 | 1 |
| Smoking status | |
| Smoker | 27 |
| Non-smoker | 5 |
| Treatment line | |
| 1st | 5 |
| 2nd | 20 |
| 3rd | 5 |
| 4th or higher | 2 |
| Previous systemic therapies (previous 3 months) | |
| Platinum-based therapy | 12 |
| Non-platinum based therapy | 8 |
| No | 12 |
| ECOG | |
| 0–1 | 25 |
| 2–4 | 7 |
| Undetermined | 0 |
| GRImScore | |
| 0–1 | 15 |
| 2–3 | 7 |
| Undetermined | 9 |
| Liver metastases | |
| No | 23 |
| Yes | 9 |
| Number of sites involved | |
| ≤2 | 9 |
| ≥3 | 23 |
| CD4 THD Profiling | |
| G1 profile | 14 |
| G2 profile | 18 |
| Responses | |
| Partial response | 10 |
| Progression disease | 19 |
| Stable disease | 3 |